Asia Pacific Autoimmune Monoclonal Antibodies Market is expected to reach USD 2,181.4 million by 2021 from USD 1,559.7 million in 2016, growing at a CAGR of 6.94% during forecast period 2016-2021.
Irregular functioning of humans’ immune system results in autoimmune disorders. Overproduction of self-reactive immune cells (such as antibodies & T-cells) damage regular functions of /cells/tissues/organs.
This lead to different autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and others diseases. Typically, drugs are used as a treatment to cure autoimmune disorders.
Full report at: www.marketdataforecast.com/market-…-antibodies-1173/
Monoclonal antibodies have the ability to offer less toxic and more efficient therapeutic alternatives to treat autoimmune diseases. Recent years have seen the emergence of monoclonal antibodies being used to treat wide array of diseases that are related to immune response.
These antibodies are mono-specific comprising of identical immune cells which are clones of a single parent cell and are directed towards a specific cellular target. Thus monoclonal antibodies due to its customizable nature can be used to treat the self-reactive immune cells not impacting the normal ones.
Rising healthcare expenditure, increasing disease patient population associated with lifestyle changes, growing involvement of universities & research institutes, rising demand for advanced healthcare therapeutics, and presence of huge population are driving the growth of autoimmune monoclonal antibodies market in Asia-Pacific. However, low adoption of advanced therapies, high cost of monoclonal antibodies therapeutics, and lack of superior research facilities in certain Asian countries are restraining the growth of autoimmune monoclonal antibodies market in Asia-Pacific.
Asia Pacific Autoimmune Monoclonal Antibodies market is segmented based on source, application, and end user. Based on source, the market is further sub-segmented as Murine, Chimeric, Humanized, and Human.
Among these, humanized segment is expected to command the largest share in Asia Pacific Autoimmune Monoclonal Antibodies market, by source in 2016. Based on application, the market is further segmented as Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Transplant Rejection/Graft Versus Host Disease, and Others.
Of these, rheumatoid arthritis application is anticipated to command the major share in Asia Pacific Autoimmune Monoclonal Antibodies market, by application in 2016. Based on end user, the market is further segmented as Hospitals/Clinics, Research Institutes, and Diagnostic Laboratories.
Among these, Hospitals/Clinics segment is expected to hold the major market share in Asia Pacific Autoimmune Monoclonal Antibodies market, by application in 2016.
Request sample: www.marketdataforecast.com/market-…73/request-sample
On the basis of geographical areas, Asia Pacific Autoimmune Monoclonal Antibodies market is segmented as Japan, China, India, South Korea, and Australia.
The key players in Autoimmune Monoclonal Antibodies market include, GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc.(U.S.), and UCB Company (Belgium).
Category: Market Research Publishers and RetailersCompany about: Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients. A few key business areas that we handle with excellence include business process improvement, corporate financing and decision making based on market research, assisting in developing appropriate strategy and providing consultancy based on extens ...
For more information:Make an Inquiry about this report HERE!